We invest in early stage health solutions leveraging the funnel of SPRIM’s sourcing, screening and selection processes.
SPRIM VENTURES benefits from SPRIM’s unique combination of skills and resouces:
Strong and long established relationships with large healthcare companies
Global infrastructure of 19 offices around the world
Potential partnerships with more than 400 global customers
Evid Science allows users to instantly compare therapy outcomes such as efficacy, safety and cost, all backed by the scientific literature. To do this, we leverage years of patent-pending research in Artificial Intelligence, to put evidence-based comparisons at your fingertips. Users can generate customized comparative effectiveness studies, on-the-fly, using either our Software-as-a-Service platform or our programmable APIs. Users can even let the system generate a landscape of all possible comparisons for a therapy (theirs or a competitor’s) covering any disease and outcome studied in the literature. Let Evid Science unlock the evidence-based insights hiding in the medical literature to power deeper marketing insights, data-driven strategy, and optimized clinical trial protocols.
Travecta Therapeutics is a company that develops novel chemistry for delivery of therapies to the brain.Travecta is based on the research of Prof. David Silver and leverages a discovery platform to identify, simplify and categorize small molecules for enabling their transport across the blood-brain barrier.
Obviohealth commercializes software solutions to help healthcare industry players substantiate health claims as well as achieve better visibility on their healthcare professional network.
ClaimIt is a proprietary digital platform that utilizes a 100% online & mobile app interface to execute clinical trials. It removes the costly overhead of physical site visits and brings the trial directly to the mobile device of each subject.
Digital Diagnostic Asia develops and commercializes non-invasive diagnostic tests in the areas of hepatology, nephrology, and metabolic conditions through in-house development and collaborations with leading scientific institutions. Our current portfolio includes algorithm-based non-invasive liver tests, LiverFACt and LiverFASt.
LiverFACt is a combination of two tests that provide METAVIR staging and necroinflammatory grading. LiverFASt is a combination of three tests, fibrosis, activity, and steatosis, providing physicians with simultaneous and complete estimation of the degree of liver injury. Our commercial focus includes direct sales activities to healthcare professionals, as well as commercial partnerships with pharmaceutical companies.
Raffiné is a proprietary e-commerce platform for Japan. It focuses solely on skin and hair care products that deliver tangible outcomes. Raffiné owns brand such as Jeune Vie and licenses from the French cosmetic leader Eugene Perma. Raffiné is headquartered in Tokyo.
Babynostics is developing diagnostics and treatment solutions based on the research of Professor David Silver at Duke-NUS on MFSD2a and Lysophospatidylcholine (LPC) lipids. His key discovery was published in Nature on May 2014: ”Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid”.